New Drug Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
New Experimental Drug, Vorasidenib, Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study IDH-mutant Glioma: Vorasidenib improves PFS in phase 3 study
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Reactions to the INDIGO data Reactions to the INDIGO data
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Gliomagenesis Mechanism of Disease Gliomagenesis Mechanism of Disease
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis. Learn more!Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
The Journey to INDIGO The Journey to INDIGO
Vorasidenib is the first targeted therapy with positive pivotal phase 3 data in patients with grade 2 IDH1/2-mutant diffuse glioma. The INDIGO study met primary and key secondary endpoints in the second interim analysis.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Novel IDH1/2 Inhibitor Shows 'Dramatic Effect' in Low-Grade Glioma
(MedPage Today) -- CHICAGO -- Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the time to next therapy, in patients with mutated, low-grade glioma, according to an interim analysis of the INDIGO... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
New drug delays progression of glioma, a deadly brain cancer
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations. (Source: World Pharma News)
Source: World Pharma News - June 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Targeted Therapy Vorasidenib Offers Hope for Deadly Brain Tumors
Summary: A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their cancer worsening, postponing the need for…#vorasidenib #idh12 #ucla #timothycloughesy #2hydroxyglutarate #idh1 #benjaminellingson #jonssoncancercenter #ingomellinghoff #patrickwen (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2023 Category: Consumer Health News Source Type: news
Vorasidenib Drug Delays Progression of Glioma Brain Cancer
A targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer (Source: Disabled World)
Source: Disabled World - June 4, 2023 Category: Disability Tags: Brain Cancers and Tumors Source Type: news
Oral Drug for Brain Tumor Could Change Treatment Landscape Oral Drug for Brain Tumor Could Change Treatment Landscape
In patients with gliomas bearing IDH1/2 mutations, the brain barrier-crossing oral drug vorasidenib kept tumors at bay, and could be used instead of more toxic chemotherapies and radiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 4, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
New drug delays progression of glioma, a deadly brain cancer
Key takeawaysA targeted therapy drug called vorasidenib had positive results in delaying progression of a specific form glioma, a slow-growing but deadly brain cancer.In a study of 331 people with the disease, the drug was effective in lengthening the period of time before the patients ’ cancer worsened, and with no observed adverse effects.New treatment approaches for glioma are needed because current treatments, including chemotherapy and radiation, can cause neurological deficits.In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a...
Source: UCLA Newsroom: Health Sciences - June 4, 2023 Category: Universities & Medical Training Source Type: news
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
BRISBANE, Calif., June 04, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the“Company”), a clinical-stage biopharmaceutical Company dedicated to developing and commercializing targeted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 4, 2023 Category: Drugs & Pharmacology Source Type: news
Chek-Mate for Gliomas
New research may make immunotherapy possible for hard-to-treat brain tumors. (Source: The Scientist)
Source: The Scientist - May 22, 2023 Category: Science Tags: News Source Type: news
